NeuroOne Medical Technologies Corporation, trading on Nasdaq as NMTC, announced it will hold a virtual investor webinar on Thursday, March 12, 2026, at 11:30 a.m. Eastern Time. The company, which focuses on transforming surgical diagnosis and treatment for neurological disorders, will have management provide a corporate update, discuss growth plans, and offer updates on its platform technologies, applications, and commercialization efforts. A question-and-answer session will follow the presentation. The implications of this announcement are significant for investors and the medical community, as NeuroOne's technologies aim to improve surgical care for neurological conditions.
The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These solutions are designed to reduce hospitalizations and surgical procedures, lower costs, and enhance patient outcomes by combining diagnostic and therapeutic functions. For more information on the company's offerings, visit nmtc1.com. During the webinar, participants can join via webcast at https://www.webcaster4.com/Webcast/Page/2914/53635 or by dialing in with the provided numbers.
The event underscores NeuroOne's ongoing efforts in research and development, including programs for drug delivery and spinal cord stimulation, which could further advance treatment options for patients. A replay of the call will be available through Thursday, March 26, 2026, accessible via the same webcast link or by phone, using replay passcode 53635. This update is crucial as it highlights the company's progress in a field where innovative medical technologies can lead to better health outcomes and economic efficiencies in healthcare. The webinar provides a platform for stakeholders to gain insights into how NeuroOne's FDA-cleared products are positioned to address complex neurological challenges, potentially reducing the burden on healthcare systems while improving surgical precision and patient recovery. By integrating diagnostic and therapeutic capabilities, these technologies represent a shift toward more efficient and effective neurological care, making this corporate update a key indicator of future developments in medical device innovation.
